Back to Stocks

ARTV

Artiva Biotherapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Artiva Biotherapeutics is transitioning from a speculative clinical-stage entity to a focused late-stage contender.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic clinical narrative, Artiva faces a daunting financial cliff. With a quarterly operating burn of approximately $24.4 million, the company's current cash reserves of $86.8 million will likely be exhausted by Q2 2027.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ARTV filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q reveals a company at a critical inflection point, where scientific validation is clashing with financial reality. The alignment with the FDA on a registrational trial design is a major catalyst that validates the AlloNK platform's potential in autoimmune diseases. However, the gap between current liquidity and the capital requirements for a global Phase 3 trial remains the primary headwind for investors. The overall impact of the filing is a shift in risk profile from 'scientific' to 'execution and financial.' While the clinical data is compelling, the market must now weigh the probability of successful Phase 3 execution against the likelihood of significant share dilution. The coming months will be defined by Artiva's ability to activate trial sites and secure the substantial capital necessary to bridge the gap to a 2028 efficacy readout.

Selected Quarter

Core Takeaway

Artiva has shifted from early-stage exploration to a defined regulatory path for refractory RA, but must solve for a significant funding gap before its 2027 cash exhaustion.

Investor Lens

The trade-off is between the high-conviction clinical data (50% ACR50) and the high-probability of significant equity dilution to fund the pivotal study.

Watch Next

Phase 3 site activation in H2 2026 and any subsequent announcements regarding strategic partnerships or capital raises.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%
bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise
80%
bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk
70%
bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression
50%

Filing History

10-QMay 8, 2026
Expand Sequence

The 10-Q reveals a company at a critical inflection point, where scientific validation is clashing with financial reality. The alignment with the FDA on a registrational trial design is a major catalyst that validates the AlloNK platform's potential in autoimmune diseases. However, the gap between current liquidity and the capital requirements for a global Phase 3 trial remains the primary headwind for investors. The overall impact of the filing is a shift in risk profile from 'scientific' to 'execution and financial.' While the clinical data is compelling, the market must now weigh the probability of successful Phase 3 execution against the likelihood of significant share dilution. The coming months will be defined by Artiva's ability to activate trial sites and secure the substantial capital necessary to bridge the gap to a 2028 efficacy readout.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.